H2-receptor antagonist
When an H2 receptor antagonist was approved as a switch OTC in September 1997, we pointed out that the medicine is improper as an OTC.
Even though pharmaceutical industries asserted that pharmacists give proper guidance on taking the medicine, we conducted a wide survey and discovered a sales practice which involved no pharmacist.
Our activities led to an administrative guidance to broaden the placement of pharmacists and to the restrictions on the medicine being advertised on TV.
Topics
- YAKUGAI Ombudsperson
- Tie-up Group
No Related Information
